Literature DB >> 33451077

Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis.

Laura Sofia Carvalho1, Nélio Gonçalves1, Nuno André Fonseca1,2, João Nuno Moreira1,3.   

Abstract

Cancer, one of the most mortal diseases worldwide, is characterized by the gain of specific features and cellular heterogeneity. Clonal evolution is an established theory to explain heterogeneity, but the discovery of cancer stem cells expanded the concept to include the hierarchical growth and plasticity of cancer cells. The activation of epithelial-to-mesenchymal transition and its molecular players are widely correlated with the presence of cancer stem cells in tumors. Moreover, the acquisition of certain oncological features may be partially attributed to alterations in the levels, location or function of nucleolin, a multifunctional protein involved in several cellular processes. This review aims at integrating the established hallmarks of cancer with the plasticity of cancer cells as an emerging hallmark; responsible for tumor heterogeneity; therapy resistance and relapse. The discussion will contextualize the involvement of nucleolin in the establishment of cancer hallmarks and its application as a marker protein for targeted anticancer therapies.

Entities:  

Keywords:  cancer stem cells; drug resistance; epithelial-to-mesenchymal transition; nucleolin; targeted therapies; tumor heterogeneity

Year:  2021        PMID: 33451077      PMCID: PMC7828541          DOI: 10.3390/ph14010060

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  185 in total

1.  Glycosilated nucleolin as marker for human gliomas.

Authors:  R Galzio; F Rosati; E Benedetti; L Cristiano; S Aldi; S Mei; B D'Angelo; R Gentile; G Laurenti; M G Cifone; A Giordano; A Cimini
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

2.  Proteomic profiling of a mouse model of acute intestinal Apc deletion leads to identification of potential novel biomarkers of human colorectal cancer (CRC).

Authors:  Abeer Hammoudi; Fei Song; Karen R Reed; Rosalind E Jenkins; Valerie S Meniel; Alastair J M Watson; D Mark Pritchard; Alan R Clarke; John R Jenkins
Journal:  Biochem Biophys Res Commun       Date:  2013-08-31       Impact factor: 3.575

3.  Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment.

Authors:  Haiquan Lu; Linh Tran; Youngrok Park; Ivan Chen; Jie Lan; Yangyiran Xie; Gregg L Semenza
Journal:  Cancer Res       Date:  2018-06-07       Impact factor: 12.701

4.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

5.  Hemagglutinin of influenza A virus binds specifically to cell surface nucleolin and plays a role in virus internalization.

Authors:  Che-Man Chan; Hin Chu; Anna Jinxia Zhang; Lai-Han Leung; Kong-Hung Sze; Richard Yi-Tsun Kao; Kenn Ka-Heng Chik; Kelvin Kai-Wang To; Jasper Fuk-Woo Chan; Honglin Chen; Dong-Yan Jin; Liang Liu; Kwok-Yung Yuen
Journal:  Virology       Date:  2016-04-14       Impact factor: 3.616

Review 6.  Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands.

Authors:  Sofia Romano; Nuno Fonseca; Sérgio Simões; João Gonçalves; João Nuno Moreira
Journal:  Drug Discov Today       Date:  2019-07-02       Impact factor: 7.851

7.  A LINE1-Nucleolin Partnership Regulates Early Development and ESC Identity.

Authors:  Michelle Percharde; Chih-Jen Lin; Yafei Yin; Juan Guan; Gabriel A Peixoto; Aydan Bulut-Karslioglu; Steffen Biechele; Bo Huang; Xiaohua Shen; Miguel Ramalho-Santos
Journal:  Cell       Date:  2018-06-21       Impact factor: 41.582

Review 8.  Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity.

Authors:  Xiao-Guang Yang; Lan-Cao Zhu; Yan-Jun Wang; Yan-Yu Li; Dun Wang
Journal:  Front Oncol       Date:  2019-09-10       Impact factor: 6.244

9.  In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

Authors:  Flavia Pichiorri; Dario Palmieri; Luciana De Luca; Jessica Consiglio; Jia You; Alberto Rocci; Tiffany Talabere; Claudia Piovan; Alessandro Lagana; Luciano Cascione; Jingwen Guan; Pierluigi Gasparini; Veronica Balatti; Gerard Nuovo; Vincenzo Coppola; Craig C Hofmeister; Guido Marcucci; John C Byrd; Stefano Volinia; Charles L Shapiro; Michael A Freitas; Carlo M Croce
Journal:  J Exp Med       Date:  2013-04-22       Impact factor: 17.579

10.  Roniciclib down-regulates stemness and inhibits cell growth by inducing nucleolar stress in neuroblastoma.

Authors:  Marzia Ognibene; Annalisa Pezzolo
Journal:  Sci Rep       Date:  2020-07-31       Impact factor: 4.379

View more
  7 in total

Review 1.  CK2 and the Hallmarks of Cancer.

Authors:  May-Britt Firnau; Angela Brieger
Journal:  Biomedicines       Date:  2022-08-16

Review 2.  Targeted contrast agents and activatable probes for photoacoustic imaging of cancer.

Authors:  Zhenxiang Zhao; Chelsea B Swartchick; Jefferson Chan
Journal:  Chem Soc Rev       Date:  2022-02-07       Impact factor: 60.615

Review 3.  Nucleolin: a cell portal for viruses, bacteria, and toxins.

Authors:  Fiorella Tonello; Maria Lina Massimino; Caterina Peggion
Journal:  Cell Mol Life Sci       Date:  2022-05-03       Impact factor: 9.207

Review 4.  Targeting Cancer Stem Cells by Dietary Agents: An Important Therapeutic Strategy against Human Malignancies.

Authors:  Mahshid Deldar Abad Paskeh; Shafagh Asadi; Amirhossein Zabolian; Hossein Saleki; Mohammad Amin Khoshbakht; Sina Sabet; Mohamad Javad Naghdi; Mehrdad Hashemi; Kiavash Hushmandi; Milad Ashrafizadeh; Sepideh Mirzaei; Ali Zarrabi; Gautam Sethi
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

Review 5.  A Mini-Review of Flavone Isomers Apigenin and Genistein in Prostate Cancer Treatment.

Authors:  Xiaozhen Ji; Kai Liu; Qingyue Li; Qun Shen; Fangxuan Han; Qingmei Ye; Caijuan Zheng
Journal:  Front Pharmacol       Date:  2022-03-11       Impact factor: 5.810

Review 6.  MicroRNAs, Tristetraprolin Family Members and HuR: A Complex Interplay Controlling Cancer-Related Processes.

Authors:  Cyril Sobolewski; Laurent Dubuquoy; Noémie Legrand
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

Review 7.  Targeting Glioblastoma Stem Cells: A Review on Biomarkers, Signal Pathways and Targeted Therapy.

Authors:  Xuejia Tang; Chenghai Zuo; Pengchao Fang; Guojing Liu; Yongyi Qiu; Yi Huang; Rongrui Tang
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.